Panbela Therapeutics RSI
¿Qué es el RSI de Panbela Therapeutics?
El RSI de Panbela Therapeutics Inc. es 48.17
¿Cuál es la definición de RSI?
El índice de fortaleza relativa (RSI 14) es un indicador de impulso que compara la magnitud de las ganancias y pérdidas durante un período de tiempo específico para medir la velocidad y el cambio de los movimientos de precios de un valor.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de compañías en Sector Health Care en NASDAQ en comparadas con Panbela Therapeutics
¿Qué hace Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Empresas con rsi similar a Panbela Therapeutics
- First Trust Exchange-Traded Fund III tiene RSI de 48.16
- World Index Shares ETFs - CSI HK 100 Tracker tiene RSI de 48.16
- Reliance Naval and Engineering tiene RSI de 48.16
- JH EDL Technology tiene RSI de 48.16
- Inter-Rock Minerals tiene RSI de 48.16
- Housing Development Finance tiene RSI de 48.16
- Panbela Therapeutics tiene RSI de 48.17
- Confederation Minerals tiene RSI de 48.18
- Apyx Medical tiene RSI de 48.18
- Sabre Corp tiene RSI de 48.18
- Esco Technologies tiene RSI de 48.18
- Primavera Capital Acquisition tiene RSI de 48.18
- Helen of Troy Ltd tiene RSI de 48.19